trial

Schizophrenia Treatment With Photoneuromodulation

NCTId NCT05339347
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 30 (actual)
Sponsored by University of Sao Paulo
Primary completion 2022-03-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2021-08-01
Primary completion
2022-03-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Photoneuromodulation

Sponsors

University of Sao PauloLead Sponsor

Investigators

1
Leandro Valiengo, PhDPrincipal Investigator

Sites

1 total
São Paulo, Brazil

Linked catalysts

1
Schizophrenia Treatment With Photoneuromodulation — primary completion2022-03-11

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE2
Primary Completion Date
2022-03-11
Status
COMPLETED
relationships
The graph out of here
drug
Photoneuromodulation
drug
lead_sponsor
University of Sao Paulo
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Leandro Valiengo, PhD
person